Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Summary

Viking Therapeutics announced the initiation of a clinical trial for VK2735 oral maintenance dosing in patients with obesity, following initial weight loss achieved with subcutaneous formulations. The study will evaluate multiple dosing regimens of both oral and subcutaneous versions of the drug.